Alpha 2.0
Login Register
» Authors » Terrance H Andree

Terrance H Andree

Explore the profile of Terrance H Andree including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 267
Followers 0
Related Specialties
Biochemistry
Chemistry
Pharmacology
Top 10 Co-Authors
Lee E Schechter
Deborah L Smith
Boyd L Harrison
Richard E Mewshaw
Dahui Zhou
Geoffrey Hornby
Deborah A Evrard
Kelly M Sullivan
Nicole T Hatzenbuhler
Rosemary Scerni
Published In
Bioorg Med Chem Lett
J Med Chem
J Pharmacol Exp Ther
Eur J Pharmacol
Bioorg Med Chem
Affiliations
Soon will be listed here.
Recent Articles
1.
The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists
Childers Jr W, Havran L, Asselin M, Bicksler J, Chong D, Grosu G, et al.
J Med Chem . 2010 May; 53(10):4066-84. PMID: 20443629
As part of an effort to identify 5-HT(1A) antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a...
2.
Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporter
Shen Z, Siva Ramamoorthy P, Hatzenbuhler N, Evrard D, Childers W, Harrison B, et al.
Bioorg Med Chem Lett . 2009 Nov; 20(1):222-7. PMID: 19932965
The structure-activity relationship (SAR) for three series of lactam-fused chroman derivatives possessing 3-amino substituents was evaluated. Many compounds exhibited affinities for both the 5-HT(1A) receptor and the 5-HT transporter. Compounds...
3.
The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa
Jackson M, Andree T, Hansard M, Hoffman D, Hurtt M, Kehne J, et al.
J Neural Transm (Vienna) . 2009 Oct; 117(1):55-67. PMID: 19809864
Dopamine replacement therapy in Parkinson's disease (PD) using L-dopa is invariably associated with a loss of drug efficacy ("wearing off") and the onset of dyskinesia. The use of dopamine receptor...
4.
Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists
Zhou D, Stack G, Lo J, Failli A, Evrard D, Harrison B, et al.
J Med Chem . 2009 Sep; 52(15):4955-9. PMID: 19719241
On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A...
5.
5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats
Sukoff Rizzo S, Pulicicchio C, Malberg J, Andree T, Stack G, Hughes Z, et al.
Int J Neuropsychopharmacol . 2009 May; 12(8):1045-53. PMID: 19435548
Sexual dysfunction associated with antidepressant treatment continues to be a major compliance issue for antidepressant therapies. 5-HT(1A) antagonists have been suggested as beneficial adjunctive treatment in respect of antidepressant efficacy;...
6.
The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach
Fan Y, Lai M, Sullivan K, Popiolek M, Andree T, Dollings P, et al.
Bioorg Med Chem Lett . 2008 Oct; 18(21):5789-91. PMID: 18849166
We identified small molecule NTS1R agonist compounds through virtual screening of the corporate database using a ROCS approach that searches multi-conformer representations efficiently. As a starting point for the ROCS...
7.
Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2
Hatzenbuhler N, Baudy R, Evrard D, Failli A, Harrison B, Lenicek S, et al.
J Med Chem . 2008 Oct; 51(21):6980-7004. PMID: 18834188
Novel compounds combining a 5-HT 1A moiety (3-aminochroman scaffold) and a 5-HT transporter (indole analogues) linked through a common basic nitrogen via an alkyl chain attached at the 1- or...
8.
D2 receptor partial agonists: treatment of CNS disorders of dopamine function
Kehne J, Andree T, Heinrich J
Curr Top Med Chem . 2008 Aug; 8(12):1068-88. PMID: 18691133
A remarkable diversity of psychiatric and neurological disorders have been associated with dysfunction of dopamine (DA)-containing neurons, including schizophrenia, bipolar disorder (BD), Parkinson's disease (PD), and restless legs syndrome (RLS)....
9.
Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives
Zhou D, Zhou P, Evrard D, Meagher K, Webb M, Harrison B, et al.
Bioorg Med Chem . 2008 Jun; 16(14):6707-23. PMID: 18571421
Based on the previously reported discovery lead, 3-(cis-4-(4-(1H-indol-4-yl)piperazin-1-yl)cyclohexyl)-5-fluoro-1H-indole (2), a series of related arylpiperazin-4-yl-cyclohexyl indole analogs were synthesized then evaluated as 5-HT transporter inhibitors and 5-HT(1A) receptor antagonists. The investigation...
10.
Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
Hirst W, Andree T, Aschmies S, Childers W, Comery T, Dawson L, et al.
J Pharmacol Exp Ther . 2008 Jan; 325(1):134-45. PMID: 18182558
5-Hydroxytryptamine (5-HT)(1A) receptors play an important role in multiple cognitive processes, and compelling evidence suggests that 5-HT(1A) antagonists can reverse cognitive impairment. We have examined the therapeutic potential of a...